The United Kingdom on Feb. 3 approved the Novavax COVID-19 vaccine for people over the age of 18.
The Medicines and Healthcare products Regulatory Agency (MHRA) granted the vaccine regulatory approval, following a “rigorous review of safety, quality, and effectiveness,” as well as advice from the Commission on Human Medicines.
“I am pleased to confirm today that this authorization has been granted, providing access to a fifth vaccine that can be used to help protect us from COVID-19,” MHRA Chief Executive June Raine said.
According to clinical trial results, the vaccine showed an efficacy of about 90% against COVID-19.
A recent study by Novavax also suggested that its vaccine provided protection that holds up much better against the Omicron variant than most other vaccines.
The UK Joint Committee on Immunization and Vaccination will now consider how the vaccine should be used in the UK COVID-19 vaccination program.
Novavax previously announced an agreement with the UK Vaccines Taskforce for up to 60 million doses of the vaccine. The government had originally expected that the doses would be available in the second half of 2021.
The Nuvovax vaccine is the first protein-based COVID-19 vaccine to be authorized for use in the UK.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.